Navigation Links
Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
Date:11/7/2013

onday, December 9, 5:00 pm CT, 393-394
  • Oral presentation: Myeloma: Therapy, excluding Transplantation II
  • Abstract # 687
  • Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Lenalidomide Extended Dosing (CRD-R) Induces High Rates of MRD Negativity in Newly Diagnosed Multiple Myeloma (MM) Patients

    • Dr. Neha Korde, Multiple Myeloma Section, National Cancer Institute, National Institutes of Health
    • Monday, December 9, 3:30 pm CT, 393-394
    • Oral presentation: Myeloma: Therapy, excluding Transplantation: Treatment Options for Newly Diagnosed Multiple Myeloma Patients
    • Abstract # 538

    Serum Heavy-Light Chains (HLC) and Free Light Chains (FLC) As Predictors For Early CR In Newly Diagnosed Myeloma Patients Treated With Carfilzomib, Lenalidomide, and Dexamethasone (CRd)

    • Dr. Manisha Bhutani, Multiple Myeloma Section, National Cancer Institute, National Institutes of Health
    • Monday, December 9, 7:30 pm CT, 393-394
    • Oral presentation: Myeloma: Therapy, excluding Transplantation: Advances in Multiple Myeloma and Plasma Cell Leukemia
    • Abstract # 762

    Phase I/II Dose Expansion of a Multi-Center Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma

    • Dr. Jatin Shah, The University of Texas MD Anderson Cancer Center
    • Monday, December 9, 5:45 pm CT, 393-394
    • Oral presentation: Myeloma: Therapy, excluding Transplantation II
    • Abstract # 690

    Carfilzomib, Rituximab and Dexamethasone (CaRD) is highly active and offers a neuropathy sparing approach for proteasome-inhibitor based the
    '/>"/>

    SOURCE Onyx Pharmaceuticals, Inc.; Amgen
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
    2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
    3. Amgen Announces 2012 First Quarter Dividend
    4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
    5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
    6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
    7. Amgen to Acquire Micromet
    8. Amgen to Present at the Leerink Swann Global Healthcare Conference
    9. Amgen Announces 2012 Third Quarter Dividend
    10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
    11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/26/2015)... 26, 2015 PRC Clinical, a Silicon-Valley ... several management and executive appointments effective immediately. , Mike ... (CFO) and member of the Board of Directors. Daniel ... and Sue Dowden will assume the position of Senior ... Chief Operations Officer (COO), has been appointed to the ...
    (Date:3/26/2015)... and CINCINNATI , March ... (LSE: SHP, NASDAQ: SHPG ) and Cincinnati ... broad research collaboration for rare diseases. The goal of ... therapies to treat rare diseases with high unmet ... with Cincinnati Children,s research expertise. As a nationally ...
    (Date:3/26/2015)... America," the popular news television program that airs in numerous ... film actor James Earl Jones, has announced that it will ... , Botany is commonly described as the scientific study of ... more complicated than that. Scientists and other professionals study a ... smallest bacteria known to man to the largest trees that ...
    (Date:3/25/2015)... (PRWEB) March 26, 2015 Agnition announced ... episode of American Farmer, airing for the first time ... segment of American Farmer will explore the extremely important ... crop producers with a patented Microbial Catalyst™ technology that ... greater yields. The segment will air again on April ...
    Breaking Biology Technology:PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 2PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 3Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 3Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 4Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 5Agnition to be Featured In Upcoming Episode of American Farmer on RFD-TV 2
    ... FDA-defined Valvulopathy Permitted to Enroll in 2nd and ... Screening Requirement Eliminated, SAN DIEGO, Dec. 13 ... announced the initiation of patient screening in,the second ... efficacy and,safety of its lead drug candidate, lorcaserin ...
    ... 13 BioMed Realty Trust, Inc.,(NYSE: BMR ) ... its,board of directors, increasing the board to eight members., ... estate industry, with a breadth of,ability and experience in ... estate projects. We believe that,Rick,s contributions to our Board ...
    ... Therapeutics today,announced the appointment of Antony Blanc, Ph.D., ... Dr Blanc, who will serve as head ... where he created and led the,biopharmaceuticals business unit. ... entrepreneur, Dr. Blanc helped biotech and pharma,clients with ...
    Cached Biology Technology:Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity 2Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity 3Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity 4Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity 5Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity 6BioMed Realty Trust Appoints Executive Officer of the Irvine Company to Its Board 2BioMed Realty Trust Appoints Executive Officer of the Irvine Company to Its Board 3Synosia Therapeutics Announces Appointment of Chief Business Officer 2
    (Date:3/24/2015)... BEACH GARDENS, Fla. , March 24, 2015 ... biometric identity management solutions, today announced that its ... premium clothing accessory retailer Goorin Bros . ... The Crossmatch biometrics-based solution secures access to the ... from the increased risk of data breaches. ...
    (Date:3/23/2015)... 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, announces its biometric payment technology, the ... CNBC television starting March 30 th . ... New York markets. ... excited about our new ad campaign following the recent initial ...
    (Date:3/20/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) ... Global Strategic Business Report" report to their offering. ... in US$ Thousands. The report provides separate comprehensive analytics for ... , Europe , Asia-Pacific ... Latin America . Annual estimates and ...
    Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
    ... The Quaking gene, first described as a mutation in ... tumor formation and protect humans from cancer. , ... the University of Wisconsin has shown that the Quaking ... a protein associated with GLI1, a cancer-causing oncogene highly ...
    ... study, Emily Oster (a graduate student in economics at ... infanticide, may not be the only cause of uncommonly ... It has long been observed that the relative number ... in the West, where it is close to unity. ...
    ... children with sore throat, exceeding the expected prevalence of ... of children who received an antibiotic prescription, according to ... , Pharyngitis (inflammation of the throat) accounts for 6 ... and pediatricians, according to background information in the article. ...
    Cached Biology News:Researchers discover new form of cancer gene regulation 2Researchers discover new form of cancer gene regulation 3Children overprescribed antibiotics for sore throat 2
    Recombinant Mouse IL-23, CF...
    ... Ambion's ActivePro In ... from an E.coli lysate, ... protein as well as ... activity than competing kits. ...
    ... Synthesis , Containing one Phospho-Amino Acid , ... customer conjugation of peptide to KLH protein , Rabbits ... , Pre-immune bleed x1 /each , ... bleed (app. 5 ml) x1 /each , ...
    Donor Goat Serum...
    Biology Products: